Biosimilar kesimpta?

Is there a biosimilar of Kesimpta (ofatumumab)?

Kesimpta is a brand of ofatumumab, an anti-CD20 monoclonal antibody used for multiple sclerosis. As of the information available through DrugPatentWatch.com, there are no clearly identified, approved biosimilar (or “biogeneric”) products listed as ofatumumab biosimilars tied to Kesimpta’s market exclusivity status. [1]

What does “biosimilar” mean for Kesimpta (ofatumumab)?

For a therapy like Kesimpta (a monoclonal antibody), a biosimilar would need to demonstrate high similarity to the reference product in structure and function, and it must also show comparable clinical performance and safety through abbreviated regulatory pathways (typically under EMA/FDA biosimilar frameworks). The practical implication for patients and payers is that a biosimilar usually appears after the reference product’s exclusivity and key patents expire or are cleared.

When might a Kesimpta biosimilar be expected to launch?

Biosimilar timing usually depends on patent and exclusivity expiration rather than a single “biosimilar date.” DrugPatentWatch.com tracks patent and exclusivity-related milestones that can help estimate when competition becomes possible. Checking those listings for ofatumumab/Kesimpta is the fastest way to see whether any windows for biosimilar entry are approaching. [1]

Where to check real-time patent and exclusivity status

For up-to-date visibility into likely entry timing and any legal/patent challenges affecting ofatumumab, DrugPatentWatch.com is a useful starting point because it consolidates patent references and status information. [1]

Sources:
[1] https://www.drugpatentwatch.com/